Japan’s MHLW Designates Three Drugs As Orphan Drugs
This article was originally published in PharmAsia News
Japan's Ministry of Health, Labour and Welfare designated three drugs as orphan drugs, including two items for one drug for different indications. They are: Otsuka's tuberculoses drug OPC-67683 for preventing multi-drug resistance, currently in Phase II trials overseas; Celgene's CC-5013 (lenalidomide) for treating multiple myeloma in Phase I trials in Japan; and Celgene's CC-5013 for treating anemia caused by myelodysplastic syndrome. MHLW also reported that Chugai's Herceptin 60 and 150 injection is expected to be approved in March. (Click for more-Japanese language
You may also be interested in...
Busy Week For Japanese Firm Otsuka: Justice Dept. Settlement For Off-Label Abilify Marketing And New Partnership With MethylGene
Abilify developer Otsuka Pharmaceutical settled with the U.S. Department of Justice over charges the company illegally marketed the atypical antipsychotic off-label for pediatric and elderly populations in the U.S. from 2002 through 2005
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.